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1	Introduction
Death	 Receptor	 3	 (DR3,	 TNFRSF25),	 along	 with	 its	 primary	 TNFSF	 ligand	 TL1A	 (TNFSF15),	 has	 recently	 emerged	 as	 a	 major	 regulator	 of	 inflammation	 and	 immunity,	 refereeing	 a	 range	 of	 cellular	 responses	 from
differentiation	and	proliferation	to	cell	death.
The	effects	of	the	DR3/TL1A	pathway	in	disease	are	both	varied	and	far-reaching.	Loss	of	DR3	has	been	shown	to	impair	both	anti-bacterial	[1]	and	anti-viral	immunity	[2],	though	conflicting	data	exists	as	to	DR3’s	impact
during	parasitic	helminth	infection	[3,4].	Most	notably,	DR3	has	been	shown	to	have	a	role	in	several	autoimmune	diseases,	including	rheumatoid	arthritis	(RA)	[5–10]	and	inflammatory	bowel	disease	(IBD)	[11–17],	both	of	which	are
considered	chronic	in	nature.	Variation	in	the	TNFRSF25	gene	locus	has	been	suggested	as	a	risk	factor	for	RA,	with	patients	displaying	elevated	TL1A	levels	in	serum	and	tissue	[5,8,9,18].	Furthermore,	an	in	vivo	antigen	induced
arthritis	model	showed	mice	genetically	deficient	 in	 the	DR3	gene	 (DR3ko)	as	presenting	with	reduced	pathology	and	 inflammatory	cell	 infiltrate	 [6,19].	This	has	been	attributed	 to	multiple	DR3-driven	 functions	which	 impact	on
effector	T	cell	development,	osteoclast	differentiation	[20]	and	cytokine/chemokine	release.	TNFSF15	has	also	been	implicated	in	other	bone	disorders	such	as	ankylosing	spondylitis	[21,22]	and	IBD	development	[23].	TL1A	levels	were
found	 to	be	up-regulated	 in	Crohn’s	disease	patients,	correlating	with	disease	progression	and	severity	 [24,25].	Those	exhibiting	high	 levels	also	suffered	 intestinal	 fibrostenosis	and	worsened	 inflammation	 in	 the	small	 intestine,
suggesting	TL1A	as	a	prognostic	marker	[17,26].	In	vivo,	mice	constitutively	expressing	TL1A	developed	colitis	or	ileitis	[17,27,28].
Asthma,	like	RA,	ankylosing	spondylitis	and	IBD,	is	considered	a	chronic	disease.	Despite	this,	the	majority	of	studies	concerning	DR3	in	allergic	lung	inflammation	have	utilised	acute	disease	models,	sufficient	to	imitate	early
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Abstract
The	Death	Receptor	3	(DR3)/Tumour	Necrosis	Factor-like	cytokine	1A	(TL1A)	axis	stimulates	effector	T	cells	and	type	2	innate	lymphocytes	(ILC2)	that	trigger	cytokine	release	and	drive	disease	pathology	in	several
inflammatory	and	autoimmune	diseases,	including	murine	models	of	acute	allergic	lung	inflammation	(ALI).	The	aim	of	this	study	was	to	elucidate	the	role	of	DR3	in	chronic	ALI	compared	to	acute	ALI,	using	mice	genetically
deficient	in	the	DR3	gene	(DR3ko).	Results	showed	DR3	expression	in	the	lungs	of	wild-type	mice	was	up-regulated	following	induction	of	acute	ALI	and	this	increased	expression	was	maintained	in	chronic	disease.	DR3ko	mice
were	resistant	to	cellular	accumulation	within	the	alveolar	passages	 in	acute,	but	not	chronic	ALI.	However,	DR3ko	mice	displayed	reduced	 immuno-histopathology	and	goblet	cell	hyperplasia;	hallmarks	of	 the	asthmatic
phenotype;	in	chronic,	but	not	acute	ALI.	These	data	suggest	DR3	is	a	potential	therapeutic	target,	involved	in	temporally	distinct	aspects	of	ALI	progression	and	pathogenesis.
airway	inflammatory	events.	DR3	was	found	to	be	central	in	the	development	of	acute	allergic	lung	inflammation,	driving	T	cell	accumulation	[29]	and	IL9	production	[30]	in	an	OVA	induced	allergic	model.	Similarly,	TL1A	was	found	to
co-stimulate	type	2	innate	lymphocyte	(ILC2)	expansion	and	promote	IL13	production	in	a	papain	allergen	model	of	acute	lung	inflammation	[3,4].	However	asthma,	due	to	its	chronic	nature,	is	typified	by	airway	remodelling	as	well	as
airway	 inflammation	[31,32].	 To	 discern	 the	 differential	 effects	 of	DR3	 in	 an	 acute	 versus	 a	more	 physiologically	 relevant	 chronic	model	 of	 allergic	 lung	 inflammation,	DR3ko	mice	were	 subjected	 to	 repeated	 allergen	 inhalation
challenges,	allowing	both	airway	infiltrating	cells	and	pathology	to	be	examined.	Our	results	show	DR3	to	be	instrumental	in	chronic	airway	remodelling,	promoting	goblet	cell	hyperplasia	and	bronchiole	pathology,	implicating	DR3	as
a	potential	therapeutic	target	in	asthmatic	disease.
2	Methods
2.1	Animals
Age-matched	female	DR3ko	and	DR3wt	littermates	of	7–12	weeks	of	age	were	used	in	experiments.	Mice	were	bred	on	a	C57BL/6	background	and	derived	from	a	DR3het	colony	that	was	founded	from	animals	provided	by	CRUK
[33].	All	procedures	were	approved	by	the	Local	Research	Ethics	Committee	and	performed	in	accordance	with	Home	Office	approved	license	PPL	30/2580.
2.2	OVA	induced	lung	inflammation
As	previously	described	[34],	mice	were	sensitised	on	days	0	and	5	via	an	i.p.	injection	containing	100	µg	chicken	OVA	(VWR)	[34]	emulsified	with	50	mg	aluminium	hydroxide	(Thermo	Scientific).	To	study	acute	pulmonary
inflammation,	on	day	15	mice	were	challenged	twice,	4	h	apart	for	1	h	via	inhalation	with	a	0.5%	(w/v)	solution	of	OVA	or	PBS.	Mice	undergoing	chronic	allergic	lung	inflammation	were	exposed	to	nebulised	2%	(w/v)	OVA	aerosol	or
PBS	for	3	days	per	week	for	6	weeks	from	day	15,	resulting	 in	a	total	of	18	 inhalation	challenges.	Each	challenge	 lasted	30	min,	excluding	the	 final	one	which	 lasted	 for	1	h.	 Inhalations	were	carried	out	 in	a	Perspex	box	 (Buxco
Electronics)	attached	to	a	Wright	nebuliser	(Pulmostar,	Devillbiss	Healthcare)	[34].	Cell	infiltration	was	evaluated	24	h	after	the	final	challenge	for	both	protocols	in	bronchoalveolar	lavage	fluid	(BALF).	Lungs	were	fixed	in	neutral
buffered	formalin	for	histological	analysis.
2.3	Flow	cytometry
Following	the	centrifugation	of	BAL	fluid	to	isolate	leukocytes,	a	total	cell	count	was	performed	using	a	Neubauer	Haemocytometer	and	trypan	blue	to	exclude	dead	cells.	Samples	were	then	treated	with	anti-CD16/32	(BD
Pharmingen)	and	stained	at	4	°C	for	25	min	with	the	following	pre	conjugated	mAbs	against	the	indicated	antigens:	MHCII-FITC,	NK1.1-FITC,	CD4-PerCP	Cy	5.5,	CD11c-PECy7,	B220-PE	Texas	Red,	Ly6G-V450,	CD44-V450,	TCRβ-APC,
CD11b-APCCy7,	CD3-APC	(all	BD	Biosciences);	7/4-PE	(AbD	Serotec),	CD8-PECy7	(Invitrogen),	F4/80-APC	(Invitrogen).	Samples	were	then	washed	before	analysis	on	a	CyAn™	ADP	Flow	cytometer	using	Summit	software	(Beckman
Coulter).	 Cell	 subsets	 were	 defined	 as	 the	 following:	 eosinophils	 (F4/80intCD11bintSSChi),	 7/4−	 monocytes	 (F4/80lowCD11bintSSClow7/4−),	 7/4+	 monocytes	 (F4/80lowCD11bintSSClow7/4+),	 myeloid	 dendritic	 cells	 (DCs)
(CD11b+CD11c+MHCII+),	CD4+	T	cells	(CD3+αβTCR+CD4+),	CD8+	T	cells	(CD3+αβTCR+CD8+),	NK	(NK1.1+αβTCR−CD3−)	and	NKT	(NK1.1+αβTCR+CD3+)	cells.
2.4	Chemokine	analysis
ELISAs	were	performed	following	manufacturers’	instructions	using	BALF	supernatant.	All	ELISAs	were	obtained	from	R&D	systems.
2.5	Histology
Lung	tissue	sections	(5	μm)	were	stained	with	haematoxylin	and	eosin	(H&E),	Periodic	acid-Schiff	(PAS)	or	Van	Gieson	stain.	H&E	stained	lungs	were	scored	according	to	a	5	point	mean	pathology	gradient;	0:	normal	lung,	1:
minor	perivascular	inflammation	and	cell	infiltrate,	2:	slight	perivascular	and	peribronchiolar	inflammation,	3:	moderate	peribronchiolar	and	perivascular	inflammation	and	airway	cuffing,	4:	marked	peribronchiolar	and	perivascular
inflammation	and	airway	cuffing,	5:	severe	peribronchiolar	inflammation,	perivascular	inflammation	and	airway	cuffing	(almost	solid	lung).	PAS	stained	sections	were	quantified	using	Leica	Qwin	V3	software,	with	the	%	of	goblet	cells
calculated	as	a	%	of	 the	airway	based	upon	positive	staining.	Van	Gieson	stained	sections	were	 judged	according	 to	 the	Ashcroft	Score	 [35];	0:	normal	 lung,	1:	minimal	 fibrosis	 thickening	of	alveolar/bronchial	walls,	3:	moderate
thickening	of	walls	without	obvious	damage	to	lung	architecture,	5:	increased	fibrosis	with	definite	damage	to	lung	architecture	and	formation	of	fibrosis	bonds/	fibrosis	masses,	7:	severe	distortion	of	architecture	and	large	fibrosis
area,	8:	total	fibrosis	obliteration	of	field.	All	lung	histology	sections	were	blind	scored	by	2	individuals	and	scores	averaged.
2.6	DR3	immunohistochemistry
Briefly,	lung	sections	(5	μm)	were	rehydrated	and	endogenous	peroxidise	activity	blocked.	Following	blocking,	sections	were	stained	with	20	μg/ml	goat	biotinylated	anti-DR3	(R&D	Systems)	or	isotype	control	for	2	h.	Positive
staining	was	visualised	using	a	streptavidin	HRP	conjugate	and	DAB	chromagen,	before	counterstaining	with	haematoxylin,	dehydration	and	mounting	in	DPX.	Images	were	captured	using	an	Olympus	Camedia	C-3030	Digital	Camera.
Staining	was	simultaneous	for	sections	and	positive	staining	threshold	was	set	using	the	isotype	control.	DR3	staining	was	quantified	using	Leica	Qwin	V3	software.	Randomly	selected	areas	were	analysed	for	positive	staining	and
calculated	as	a	%	of	the	total	lung	area	shown.
2.7	Statistical	analysis
All	results	are	presented	as	the	mean	±	the	standard	error	of	the	mean	(SEM)	and	were	analysed	using	GraphPad	Prism	v5.	Unpaired	t	tests	and	two-way	ANOVAs	with	Bonferroni	post	hoc	test	were	used	for	analyses	with	more
than	1	variable.	P	values	of	<0.05	were	considered	significant:	∗denotes	p	<	0.05,	∗∗denotes	p	<	0.01,	∗∗∗denotes	p	<	0.001.
3	Results
3.1	DR3	is	significantly	up-regulated	in	the	lung	in	acute	but	not	chronic	allergic	lung	inflammation
The	DR3/TL1A	pathway	has	been	proved	essential	to	the	development	of	airway	inflammation	in	an	acute	model	of	lung	disease	[4,29,36].	Nonetheless,	little	is	known	about	the	expression	patterns	of	DR3	in	the	lung	following
OVA	 induced	 inflammation.	 To	 examine	 DR3	 expression	 in	 the	 lung	 following	 both	 acute	 and	 chronic	 OVA	 induced	 inflammation,	 immuno-histochemical	 analysis	 was	 used.	 DR3	 expression	 was	 found	 to	 be	 focused	 within	 the
peribronchiolar	areas	of	the	lung,	with	occasional	signal	noted	in	the	alveolar	spaces	(Fig.	1a).	DR3wt	acute	OVA-treated	lungs	expressed	6.5	±	3.0%	DR3,	significantly	more	than	PBS-treated	controls	(1.2	±	0.1%)	(Fig.	1c).	Conversely,
DR3wt	mice	undergoing	chronic	OVA	treatments	displayed	analogous	DR3	levels	to	PBS	controls	but	significantly	more	than	DR3ko	mice,	with	expression	again	focused	in	the	bronchiolar	epithelium	and	occasionally	the	smooth	muscle
(Fig.	1b).	Therefore,	whilst	the	locality	of	DR3	was	similar	in	acute	and	chronically	treated	lungs,	differences	in	the	degree	of	expression	were	only	observed	in	the	acute	model.
Fig.	1	DR3	expression	in	the	lung	following	acute	and	chronic	allergic	lung	inflammation.	Following	OVA	induced	allergic	lung	inflammation,	lungs	were	perfused,	harvested,	fixed,	sectioned	and	stained	for	DR3	expression.	Representative	pictures	showing	DR3	staining	in	the	lungs
of	DR3wt	and	DR3ko	OVA	treated	mice	along	with	DR3wt	and	DR3ko	PBS	challenged	controls	(A)	24	h	after	acute	allergic	lung	inflammation	and	(B)	24	h	after	chronic	allergic	lung	inflammation	(scale	bar	=	100	µm).	(C)	Summary	of	DR3	expression	in	acute	and	chronically	treated
lungs.	For	acute	lung	inflammation,	both	genotype	(p	<	0.05)	and	inhalation	treatment	(p	<	0.05)	significantly	effect	DR3	expression.	For	chronic	lung	inflammation,	genotype	is	a	significant	factor	concerning	DR3	expression	(**p	<	0.01),	whilst	OVA/PBS	inhalation	treatment	shows
3.2	DR3	regulates	cellular	accumulation	into	the	alveolar	passage	in	acute	but	not	chronic	allergic	lung	inflammation
DR3ko	mice	or	mice	treated	with	anti-TL1A	blocking	antibody,	have	been	shown	to	be	resistant	to	cellular	accumulation	in	the	alveolar	passage	following	sensitisation	and	acute	challenge	with	OVA.	Our	data	is	consistent	with
these	results,	as	in	our	acute	model,	DR3ko	OVA	treated	mice	had	1.5	±	0.3	×	105	cells	within	the	BALF,	significantly	less	than	the	4.8	±	1.4	×	105	cells	recorded	in	DR3wt	OVA	treated	mice	and	equivalent	to	the	PBS	controls	in	both
DR3wt	and	DR3ko	mice	(Fig.	2b).	In	contrast,	in	the	chronic	allergic	lung	inflammation	model,	no	significant	differences	were	found	in	BALF	cell	number	between	DR3wt	and	DR3ko	groups,	irrespective	of	whether	they	were	challenged
with	OVA	or	control	PBS	(Fig.	2d).	Analysis	of	individual	cell	subsets	following	the	induction	of	acute	allergic	lung	inflammation	revealed	DR3ko	OVA	mice	had	significantly	fewer	cells	of	both	myeloid	and	lymphocytic	origin,	including
eosinophils,	7/4−	monocytes,	myeloid	dendritic	cells	(DCs),	CD4+,	CD8+	and	NKT	cells.	However,	7/4+	monocytes	and	NK	cells,	though	diminished,	were	not	significantly	lower	(Fig.	3a).	Despite	the	broad	range	of	cell	types	affected,	the
decrease	in	DR3ko	cell	numbers	following	acute	OVA	challenge	was	not	due	to	defective	chemokine	production	as	seen	in	acute	peritoneal	inflammation	[37],	as	no	disparities	were	seen	in	CCL3,	CCL4,	CCL5,	CXCL1,	CXCL2,	CXCL10
or	CXCL13	levels	in	the	BALF	following	the	induction	of	lung	inflammation	(Table	1).	In	contrast,	although	chronic	OVA	challenged	DR3ko	mice	exhibited	reduced	CD4+	and	CD8+	T	cell	numbers	compared	to	DR3wt	mice,	this	decrease
was	not	significant	(Fig.	3b).	Thus,	whilst	DR3	is	absolutely	required	for	inflammatory	cell	infiltration	following	acute	OVA	challenge,	it	has	a	limited	effect	following	chronic	OVA	aerosolisations,	which	in	general	showed	little	cellular
accumulation	regardless	of	the	presence	of	DR3.
no	significant	effect.	Mean	%	positive	(brown)	pixels	within	the	lung	shown	±	SEM	(n	=	5	DR3wt	and	DR3ko	mice	per	treatment).	Significant	differences	were	identified	using	two-way	ANOVA	with	Bonferroni	post-test	comparing	DR3	expression	in	acute	and	chronic	experiments.	(For
interpretation	of	the	references	to	colour	in	this	figure	legend,	the	reader	is	referred	to	the	web	version	of	this	article.)
Fig.	2	Total	cell	number	in	bronchoalveolar	lavage	fluid	of	DR3wt	and	DR3ko	mice	following	acute	and	chronic	allergic	lung	inflammation.	Following	OVA	induced	allergic	lung	inflammation,	cells	were	isolated	from	the	alveolar	passage	via	lavage	and	counted.	(A)	Timeline	of	acute
allergic	lung	inflammation	sensitisation	and	challenge.	(B)	Total	cell	number	in	BALF	24	h	after	the	final	inhalation	challenge	in	acute	protocol.	*p	<	0.05	using	t	test	comparing	DR3wt	and	DR3ko	OVA	challenged	mice.	(C)	Timeline	of	chronic	allergic	lung	inflammation	sensitisation
and	challenge.	(D)	Total	cell	number	in	BALF	24	h	after	final	inhalation	challenge	in	chronic	protocol.
Table	1	Chemokine	levels	within	the	BAL	of	DR3wt	and	DR3ko	mice	following	acute	and	chronic	allergic	lung	inflammation.	Following	OVA-induced	allergic	lung	inflammation,	BAL	fluid	was	isolated	and	the
supernatant	used	to	determine	chemokine	levels	using	ELISA.	No	significant	differences	were	seen.	Significance	determined	using	t	test	comparing	DR3wt	and	DR3ko	OVA	challenged	groups.	Values	represents
mean	±	SEM	(n	=	6	DR3wt	and	DR3ko	mice	per	treatment).
Chemokine DR3wt DR3ko Significance$
PBS* OVA^ PBS* OVA^
Acute CCL3 N/A† N/A† N/A† N/A† N/A†
CCL4 N/A† N/A† N/A† N/A† N/A†
CCL5 74	±	18 92	±	10 77	±	15 78	±	18 p	=	0.55	N.S.D
CXCL1 N/A† N/A† N/A† N/A† N/A†
CXCL2 90	±	21 107	±	7 144	±	55 85	±	18 p	=	0.41	N.S.D
CXCL10 310	±	36 342	±	26 359	±	72 275	±	33 p	=	0.15	N.S.D
CXCL13 229	±	34 275	±	51 456	±	180 292	±	39 p	=	0.79	N.S.D
Chronic CCL3 36	±	10 31	±	5 38	±	4 27	±	3 p	=	0.46	N.S.D
CCL4 N/A† N/A† N/A† N/A† N/A†
Fig.	3	Leukocyte	cell	subset	numbers	in	bronchoalveolar	lavage	fluid	of	DR3wt	and	DR3ko	mice	following	acute	and	chronic	allergic	lung	inflammation.	Cell	subsets	numbers	were	calculated	from	BALF	using	cell	counts	and	flow	cytometry.	(A)	Individual	cell	subsets	labelled
eosinophils	(*p	<	0.05),	7/4−	monocytes	(*p	<	0.05),	7/4+	monocytes,	myeloid	DCs	(*p	<	0.05),	CD4+	T	cells	(**p	<	0.01),	CD8+	T	cells	(***p	<	0.001),	NK	cells	and	NK	T	cells	(*p	<	0.05).	Significance	tested	using	t	test	comparing	DR3wt	and	DR3ko	OVA	challenged	mice.	(B)	Individual
cell	subsets	labelled	eosinophils,	7/4−	monocytes,	7/4+	monocytes,	myeloid	DCs,	CD4+	T	cells,	CD8+	T	cells,	NKT	cells	and	NK	cells.	Values	represent	mean	±	SEM.	Each	symbol	represents	data	from	a	single	mouse.
CCL5 145	±	40 125	±	22 138	±	21 96	±	11 p	=	0.26	N.S.D
CXCL1 74	±	16 45	±	6 63	±	5 48	±	8 p	=	0.79	N.S.D
CXCL2 254	±	54 216	±	20 272	±	18 185	±	25 p	=	0.35	N.S.D
CXCL10 799	±	144 955	±	246 941	±	90 666	±	64 p	=	0.28	N.S.D
CXCL13 551	±	99 556	±	46 716	±	32 483	±	65 p	=	0.37	N.S.D
N.S.D	=	no	significant	difference.
* PBS	corresponds	to	mice	challenged	via	inhalation	with	PBS.
^OVA	corresponds	to	mice	challenged	via	inhalation	with	OVA.†N/A	corresponds	to	chemokines	either	not	being	present	or	below	detection	range.
$ Significance	between	DR3wt	and	DR3ko	OVA	treated	groups	tested	using	t	test.
3.3	DR3	enhances	airway	pathology	and	goblet	cell	hyperplasia	in	chronic	allergic	lung	inflammation
To	determine	the	pathological	consequences	of	DR3	signalling	in	the	lung	following	OVA	acute	and	chronic	challenge,	we	used	histological	analysis	to	assess	general	pathology,	including	goblet	cell	hyperplasia	and	fibrosis,
both	of	which	represent	airway	remodelling.	This	complex	and	dynamic	process	is	thought	to	contribute	to	the	dysregulation	of	airway	function,	therefore	prolonging	the	allergic	response	and	typifying	human	asthma.	H&E	staining
was	used	 to	assess	general	 lung	pathology.	Staining	revealed	 that	although	DR3	had	no	role	 in	acute	airway	 inflammation	pathology	 (Fig.	4a),	 in	chronic	allergic	 lung	 inflammation,	DR3koOVA	challenged	mice	exhibited	 less	 lung
inflammation	compared	to	DR3wt	OVA	mice;	2.5	±	0.3	vs	4.5	±	0.3,	respectively	(Fig.	4b	and	c).	Both	inhalation	treatment	and	genotype	were	deemed	significant	by	two-way	ANOVA,	as	was	the	interaction	between	the	two	variables.
This	was	highlighted	by	decreased	peribronchial	inflammation	and	cellular	cuffing	of	the	DR3ko	OVA	challenged	airways	(Fig.	4b).	To	quantitate	levels	of	mucin	producing	goblet	cells,	lungs	were	stained	with	Periodic	acid-Schiff	(PAS)
and	evaluated	using	software	to	identify	positive	(pink)	areas.	Analysis	of	goblet	cells	following	acute	allergic	lung	inflammation	indicated	no	significant	differences	between	DR3wt	and	DR3ko	OVA	treated	lungs	(Fig.	5a).	However,	DR3ko
lungs	subjected	to	chronic	OVA	challenge	had	significantly	less	mucin-producing	cells	than	their	DR3wt	counterparts	(Fig.	5b	and	c),	as	again	a	significant	interaction	was	noted	between	inhalation	treatment	and	genotype.	Lungs	were
also	stained	with	Van	Gieson	solution	to	assay	the	level	of	collagen	and	thereby	acquire	an	arbitrary	measure	of	fibrosis.	These	levels	were	scaled	against	the	Ashcroft	score	of	fibrosis	[35].	There	was	no	significant	differences	between
the	lungs	of	OVA	sensitised	and	challenged	DR3ko	mice	compared	to	DR3wt	mice	in	either	the	acute	or	chronic	models	of	lung	inflammation	(Fig.	6).	Unsurprisingly	however,	mice	subjected	to	multiple	OVA	inhalations	presented	with
higher	fibrotic	scores	than	mice	that	had	undergone	the	acute	protocol,	regardless	of	genotype.	Our	data	shows	that	absence	of	DR3	protects	against	the	development	of	certain	aspects	of	severe	immunopathology	in	repeated	OVA
induced	chronic	 lung	 inflammation.	While	Whilst	fibrosis	was	not	different,	goblet	cell	hyperplasia	and	cellular	 infiltration	 in	 the	perivascular,	 interstitial	and	peribronchial	 regions	were	substantially	reduced	 in	chronic	DR3ko	OVA
treated	mice,	suggesting	DR3	as	important	for	the	development	of	some,	but	not	all,	pathological	aspects	in	the	airway	remodelling	process.
Fig.	4	Lung	pathology	of	DR3wt	and	DR3ko	mice	following	acute	and	chronic	allergic	lung	inflammation.	Following	OVA	induced	allergic	lung	inflammation,	lungs	were	perfused,	harvested,	fixed,	sectioned	and	stained	with	H&E	for	histological	evaluation.	(A)	Representative	pictures
of	H&E	stained	lungs	(scale	bar	=	250	µm)	following	acute	challenge	with	OVA	or	PBS	(as	labelled).	(B)	Representative	pictures	of	H&E	stained	lungs	(scale	bar	=	250	µm)	following	chronic	OVA	or	PBS	challenge	(as	labelled).	(C)	Summary	of	pathology	scores	for	acute	and	chronic
H&E	stained	lungs.	For	acute	lung	inflammation,	inhalation	treatment	is	significant	for	lung	pathology	(**p	<	0.01),	whilst	genotype	is	not.	For	chronic	lung	inflammation,	both	inhalation	(**p	<	0.01)	and	genotype	display	significance,	as	DR3ko	OVA	treated	lungs	showed	significantly
less	inflammation	than	DR3wt	OVA	challenged	(*p	<	0.05).	Lungs	were	blind	scored	by	two	individuals	for	pathology	and	an	average	taken	for	each	lung.	Results	analysed	using	two-way	ANOVA	with	Bonferroni	post-test.	Data	represents	mean	±	SEM	(n	=	4	to	–6	DR3wt	and	DR3ko
mice	per	treatment).
Fig.	5	Goblet	cell	hyperplasia	in	the	lungs	of	acute	and	chronically	challenged	DR3wt	and	DR3ko	mice.	Following	OVA	induced	allergic	lung	inflammation,	lungs	were	perfused,	harvested,	fixed,	sectioned	and	stained	with	Periodic	acid-Schiff	(PAS)	for	histological	evaluation.	(A)
Representative	photos	of	PAS	stained	lungs	(scale	bar	=	100	µm)	following	OVA	or	PBS	control	induced	acute	allergic	lung	inflammation	(as	labelled).	(B)	Representative	pictures	of	PAS	stained	lungs	(scale	bar	=	100	µm)	following	chronic	OVA	or	PBS	challenge.	(C)	Summary	of
goblet	cell	positive	areas	in	acute	and	chronic	allergic	lung	inflammation.	Following	acute	inflammation,	neither	inhalation	treatment	nor	genotype	proved	significant.	Analysis	of	chronically	challenged	lungs	showed	DR3wt	OVA	samples	to	have	significantly	more	mucin	producing
goblet	cells	than	DR3ko	OVA	aerosolised	mice,	as	genotype	was	a	significant	factor	(*p	<	0.05).	Inhalation	treatment	was	also	significant,	as	OVA	treated	mice	had	more	goblet	cells	than	PBS	challenged	animals	(***p	<	0.001).	The	area	of	PAS+	cells	was	taken	as	a	%	of	the	area
surround	and	an	average	calculated	for	each	lung.	Results	analysed	using	two-way	ANOVA	with	Bonferroni	post-test.	Data	represents	mean	±	SEM	(n	=	4	to	–6	DR3wt	and	DR3ko	mice	per	treatment).
Fig.	6	Fibrosis	assessment	of	DR3wt	and	DR3ko	lung	following	acute	and	chronic	allergic	lung	inflammation.	Following	OVA	induced	allergic	lung	inflammation,	lungs	were	perfused,	harvested,	fixed,	sectioned	and	stained	with	Van	Gieson	solution	for	histological	evaluation.	(A)
Representative	photos	of	Van	Gieson	stained	lungs	(scale	bar	=	100	µm)	post	acute	allergic	lung	inflammation	(as	labelled).	(B)	Representative	pictures	of	Van	Gieson	stained	lungs	(scale	bar	=	100	µm)	following	chronic	OVA	or	PBS	challenge	(as	labelled).	(C)	Summary	of	fibrotic
scores	in	acute	and	chronic	lungs.	Neither	genotype	nor	inhalation	treatment	proved	significant	following	acute	allergic	lung	inflammation.	Following	chronic	allergic	lung	inflammation,	inhalation	treatment	was	shown	to	be	significant	to	fibrosis	development	as	OVA	challenged	mice
4	Discussion
The	importance	of	DR3/TL1A	in	animal	models	of	acute	allergic	lung	disease	are	well	established,	despite	asthma	predominantly	being	considered	a	chronic	syndrome.	The	results	of	this	study	indicate	that	whilst	DR3	induces
a	multitude	of	effects	upon	the	induction	of	allergic	lung	inflammation,	these	are	highly	dependent	upon	the	model	employed.	In	acute	disease,	DR3	was	found	to	be	responsible	for	cellular	accumulation	in	the	alveolar	passage.	This
was	 concurrent	 with	 DR3	 up-regulation	 in	 the	 lung.	 Interestingly	 however,	 during	 the	 chronic	 phase	 of	 disease,	 DR3	 promoted	 airway	 remodelling	 via	 goblet	 cell	 hyperplasia	 and	 immuno-pathology,	 including	 bronchiole	 and
parenchyma	cell	infiltration.
Models	 of	 acute	 allergic	 lung	 inflammation	have	 long	been	employed	 to	 identify	 the	mechanisms	underlying	 the	 immunological	 and	 inflammatory	 responses	 of	 asthma,	 replicating	 the	 initiating	 events	 leading	 to	 disease.
Multiple	studies	have	previously	identified	DR3	as	a	regulator	of	BALF	cell	accumulation,	citing	ILC2	[3,4],	Th2	[29,36]	and	Th9	cells	[30]	as	perpetrators.	Data	shown	here	concurs	with	published	results,	as	DR3ko	allergen	challenged
mice	exhibited	reduced	numbers	of	multiple	cell	types	including	eosinophils	and	CD4+	T	cells.	Furthermore,	increased	DR3	expression	observed	in	DR3wt	OVA	challenged	lungs	may	be	linked	to	the	increased	numbers	of	leukocytes	in
BALF,	many	of	which	are	known	to	express	DR3	[2,36].	Multiple	human	studies	have	reported	up-regulation	of	DR3	in	tissues	in	inflammatory	conditions,	including	psoriatic	skin	lesions	[38]	and	renal	tubular	epithelial	cells	during
acute	transplant	rejection	[39].	Furthermore,	recent	human	studies	show	DR3	to	be	highly	expressed	in	lung	biopsies	obtained	from	active	sarcoidosis	patients	[40],	whilst	in	a	murine	model,	TL1A	has	been	shown	to	be	expressed
following	papain	induced	lung	inflammation	[30].	However,	this	is	the	first	report	of	DR3	expression	in	the	murine	lung,	and	more	importantly,	its	increased	expression	in	response	to	inflammation.	Despite	the	differences	noted	in	DR3
expression	following	acute	ALI,	equivalent	degrees	of	lung	immuno-pathology	were	noted	between	DR3wt	and	DR3ko	OVA	acute	challenged	mice.	This	is	in	contrast	to	previous	published	data,	which	described	reduced	histopathology
scores,	including	peribronchial	inflammation	in	DR3ko	mice	[29]	whilst	dominant	negative	DR3	lungs	exhibited	reduced	numbers	of	infiltrating	cells	around	blood	vessels	and	bronchiole	[36].	There	are	several	possible	reasons	for	this
discrepancy,	the	most	likely	being	the	use	of	different	sensitisation	and	challenge	protocols,	which	have	previously	been	suggested	as	a	reason	for	conflicting	results	within	the	literature	of	murine	asthma	models	[41].	Meylan	et	al.
sensitised	mice	with	an	OVA/Alum	mix	on	days	0	and	7,	followed	by	an	intra-tracheal	challenge	on	day	14	and	intranasal	challenge	on	day	15	[29]	whereas	here,	mice	were	sensitised	with	an	OVA/Alum	emulsion	on	days	0	and	5,
followed	by	two	OVA	aerosolisation	challenges	on	day	15.	Comparing	these	protocols,	possibly	the	largest	immunological	impact	may	come	from	the	route	of	final	antigenic	challenge.	Intratracheal/intranasal	challenge	would	lead	to	a
larger	antigenic	dose	in	the	upper	airways,	while	whilst	aerosolisation	would	supply	smaller	doses	diffusely	to	the	lower	airways	[42,43].	Overall,	it	appears	that	whilst	short-term	exposure	is	sufficient	to	imitate	airway	inflammatory
events	[44],	the	model	of	acute	allergic	lung	inflammation	employed	herein	does	not	exhibit	the	characteristics	of	airway	remodelling,	which	generally	occur	as	a	result	of	chronic	exposure.
Asthma	is	defined	as	a	disease	of	the	airways,	characterised	by	airway	inflammation,	airway	hyper-responsiveness	and	airway	remodelling	[45].	Although	no	single	in	vivo	model	is	able	to	replicate	all	of	these	morphological
and	functional	features,	animal	models	have	been	used	to	study	specific	aspects	of	the	disease.	In	this	model	of	chronic	allergic	lung	inflammation,	it	was	found	that	airway	inflammation,	studied	via	cell	accumulation,	and	allergic
antibody	production	(data	not	shown)	were	not	DR3	dependent.	This	 is	 further	supported	by	the	 lack	of	differences	noted	 in	chemokine	concentrations,	which	were	previously	 identified	as	DR3	dependent	during	acute	peritoneal
fibrosis	[37]	but	not	after	viral	challenge	[2].	Moreover,	none	of	the	BALF	cell	subsets	studied	differed	significantly	between	DR3wt	and	DR3ko	mice	following	multiple	OVA	aerosolisation	challenges.	This	is	a	common	occurrence	when
modelling	chronic	allergic	lung	protocols,	which	continue	to	be	problematic	in	exhibiting	all	the	characteristics	of	human	asthma	[46].	Koerner-Rettberg	et	al.	noted	sustained	airway	lymphocytosis	but	short	lived	eosinophilia	upon	long
term	challenge	[47].	Meanwhile,	Swirski	et	al.	describes	diminishing	eosinophilia	by	3	weeks	and	complete	resolution	after	4	weeks	of	antigen	exposure	 [48],	 suggesting	 that	 chronic	 exposure	 to	 antigen	does	not	 sustain	 airway
inflammation	but	rather	leads	to	airway	unresponsiveness	[49].	This	apparent	lack	of	contribution	to	airway	inflammation	after	multiple	aerosol	challenges	is	not	just	restricted	to	DR3	amongst	the	TNFRSF.	TNFRko	mice	also	showed
no	differences	compared	to	WT	mice	in	BAL	leukocyte	numbers	after	7	days	of	consecutive	OVA	aerosolisation,	suggesting	that	removal	of	TNFα	signalling	alone	is	unable	to	abrogate	allergic	lung	inflammation	and	other	cytokines
have	the	ability	to	compensate	for	its	loss	[50].	Furthermore,	though	not	studied	here,	regulatory	T	cells	(Treg)	may	also	have	contributed	to	the	lack	of	airway	inflammation	seen.	Functional	effects	of	DR3	signalling	on	the	Treg	subset
have	been	studied,	as	both	an	agonistic	DR3	antibody	[51]	and	TL1A-IgG	fusion	protein	[52]	were	reported	to	expand	the	pool	of	Tregs	within	the	lung,	reversing	the	ratio	of	conventional	T	cells	to	Tregs.	This	was	reported	to	lead	to	the
suppression	of	acute	allergic	lung	inflammation	[51],	a	phenomenon	which	could	also	be	active	in	the	chronic	stages	of	disease.	Having	said	this,	mice	constitutively	expressing	TL1A	on	DCs	displayed	increased	Treg	turnover,	with	pro-
inflammatory	signals	over-riding	suppressive	effects	[28],	suggesting	the	relationship	between	DR3/TL1A	and	Tregs	as	both	complex	and	not	well	defined.
Whilst	 chronic	models	 of	 allergic	 lung	 disease	 have	 been	 shown	 to	 have	modest	 levels	 of	 infiltration,	 airway	 remodelling	 is	 considered	 a	 fundamental	 feature	 of	 the	 disease.	 Intriguingly,	 despite	 flow	 cytometry	 results
suggesting	few	differences	 in	BALF	leukocyte	accumulation,	H&E	stained	lung	tissue	showed	greater	cellular	 infiltration	in	the	peribronchial	and	perivascular	areas	of	DR3wt	OVA	challenged	mice,	 implying	DR3	is	 involved	in	the
regulation	 of	 lung	 pathology.	 There	 may	 be	 several	 reasons	 why	 BALF	 cell	 infiltration	 and	 pathology	 scores	 do	 not	 correlate,	 the	 first	 being	 due	 to	 the	 compartmentalised	 nature	 of	 the	 lung	 [53].	 The	 lavage	 of	 the
bronchoalevolarbronchoalveolar	space	is	unlikely	to	represent	the	whole	lung,	hence	the	importance	of	whole	lung	pathology,	as	assessed	here	by	H&E	staining.	Secondly,	only	immune	cells	were	analysed	in	the	BALF	fluid	obtained
displayed	significantly	more	fibrosis	than	PBS	treated	lung	(***p	<	0.001).	Genotype	was	not	a	significant	factor.	Lungs	were	blind	scored	by	two	individuals	using	Ashcroft	score	of	fibrosis	and	an	average	taken	for	each	lung.	Results	analysed	using	two-way	ANOVA	with	Bonferroni
post-test.	Data	represents	mean	±	SEM	(n	=	4	to	–6	DR3wt	and	DR3ko	mice	per	treatment).
following	the	induction	of	allergic	lung	inflammation.	The	increased	infiltration	observed	by	histology	could	be	due	to	an	increase	in	structural	cells	such	as	fibroblasts,	which	have	been	shown	to	contribute	to	inflammatory	events
within	the	lung	[54,55].	However,	without	more	immuno-histochemical	staining	using	Abs	that	specifically	identify	such	cells,	this	is	difficult	to	assess.
As	well	as	general	lung	pathology,	DR3ko	OVA	challenged	mice	also	had	lower	levels	of	mucin	producing	goblet	cells	than	DR3wt	OVA	mice	following	chronic	allergic	lung	inflammation.	Mucin	production	is	a	key	contributor	to
asthma	and	via	the	production	of	mucus	plugs,	also	to	 fatalities	 [49,56].	DR3	has	already	been	shown	to	have	a	role	 in	goblet	cell	hyperplasia,	albeit	 in	a	model	of	small	 intestinal	 inflammation	[26–28].	Mice	which	constitutively
expressed	TL1A	on	both	T	cells	[27]	and	DCs	[28]	spontaneously	developed	small	bowel	disease	which	was	characterised	by	goblet	cell	hypertrophy	and	hyperplasia,	thought	to	be	IL-13	driven.	More	recently,	Moltke	et	al.	suggest
small	intestine	epithelial	tuft	cell	derived	signals	to	be	the	key	activators	of	ILC2s	and	thereby	IL-13	and	goblet	cell	hyperplasia	[57],	suggesting	perhaps	TL1A	could	be	released	by	tuft	cells	and	activate	ILC2s	in	this	manner.
When	studying	 the	 fibrotic	response,	 there	were	no	significant	differences	 in	collagen	production	between	DR3wt	and	DR3ko	OVA	mice.	The	DR3/TL1A	pathway	has	previously	been	shown	 to	be	 involved	 in	both	 intestinal
[13,17,26,58]	and	peritoneal	fibrosis	[37].	Mice	which	constitutively	expressed	TL1A	exhibited	enhanced	gut	fibrosis	compared	to	WT	mice	[13],	which	correlated	with	an	increase	in	TGFβ1	[26],	a	known	mediator	of	fibrosis	[59].
Similarly	in	the	peritoneum,	DR3wt	mice	which	received	multiple	inflammatory	challenges	displayed	thickening	of	the	peritoneal	mesothelial	layer	and	increased	deposition	of	collagen	[37].	Interestingly,	other	TNFR	members	have
been	found	to	have	a	role	in	the	fibrotic	response	during	chronic	allergic	lung	inflammation.	Inhibition	of	LIGHT	led	to	a	reduction	in	the	level	of	fibrosis	as	well	as	smooth	muscle	mass,	thought	to	be	mediated	via	the	inhibition	of	TGFβ
and	 IL-13	 release	 [60].	 Similarly,	 TNFR	 p55/p75	 deficient	mice	 demonstrated	 significantly	 reduced	 peribronchial	 fibrosis,	 smooth	muscle	 layer	 and	 deposition	 of	 extracellular	matrix	 proteins	 in	 a	model	 of	 chronic	 allergic	 lung
inflammation	[61].	The	lack	of	differences	shown	here	suggests	that	amongst	the	TNFRSF,	DR3	is	not	essential	for	the	initiation	and	development	of	lung	fibrosis.
The	relationship	between	airway	inflammation	and	airway	remodelling	is	poorly	understood.	This	is	made	more	difficult	by	the	variety	of	sensitisation	and	challenge	protocols	used	as	well	as	the	array	of	read-outs	used	to
assess	the	responses.	Data	here	corroborates	published	literature	stating	that	loss	of	DR3	function	ameliorates	acute	allergic	lung	inflammation,	shown	by	reduced	cellular	infiltration	into	the	BALF.	In	a	more	clinically	relevant	model
of	chronic	allergic	lung	inflammation,	DR3ko	OVA	mice	exhibited	lower	mucin	levels	and	inflammation	in	the	lung	parenchyma	compared	to	DR3wt	mice,	although	the	underlying	mechanisms	behind	this	are	unknown.	This	is	the	first
report	of	DR3	in	chronic	allergic	lung	inflammation	and	its	potential	as	a	therapeutic	target	for	antagonism	of	goblet	cell	hyperplasia	and	associated	mucus	over-production	as	a	result	of	allergic	disease.Acknowledgments
The	authors	gratefully	acknowledge	the	Central	Biotechnology	Service,	School	of	Medicine,	Cardiff	University	for	access	to	flow	cytometers	and	to	members	of	our	animal	facilities	for	the	care	of	animals	used
in	these	studies.References
[1]	S.L.	Buchan,	V.Y.	Taraban,	T.J.	Slebioda,	S.	James,	A.F.	Cunningham	and	A.	Al-Shamkhani,	Death	receptor	3	is	essential	for	generating	optimal	protective	CD4(+)	T-cell	immunity	against	Salmonella,	Eur.	J.	Immunol.	42,
2012,	580–588.
[2]	J.P.	Twohig,	M.	Marsden,	S.M.	Cuff,	J.R.	Ferdinand,	A.M.	Gallimore,	W.V.	Perks,	A.	Al-Shamkhani,	I.R.	Humphreys	and	E.C.	Wang,	The	death	receptor	3/TL1A	pathway	is	essential	for	efficient	development	of	antiviral	CD4(+)
and	CD8(+)	T-cell	immunity,	FASEB	J.	26,	2012,	3575–3586.
[3]	X.	Yu,	R.	Pappu,	V.	Ramirez-Carrozzi,	N.	Ota,	P.	Caplazi,	J.	Zhang,	D.	Yan,	M.	Xu,	W.P.	Lee	and	J.L.	Grogan,	TNF	superfamily	member	TL1A	elicits	type	2	innate	lymphoid	cells	at	mucosal	barriers,	Mucosal	Immunol.	7,	2014,
730–740.
[4]	F.	Meylan,	E.T.	Hawley,	L.	Barron,	J.L.	Barlow,	P.	Penumetcha,	M.	Pelletier,	G.	Sciume,	A.C.	Richard,	E.T.	Hayes,	J.	Gomez-Rodriguez,	X.	Chen,	W.E.	Paul,	T.A.	Wynn,	A.N.	McKenzie	and	R.M.	Siegel,	The	TNF-family	cytokine	TL1A
promotes	allergic	immunopathology	through	group	2	innate	lymphoid	cells,	Mucosal	Immunol.	7,	2014,	958–968.
[5]	G.	Bamias,	S.I.	Siakavellas,	K.S.	Stamatelopoulos,	E.	Chryssochoou,	C.	Papamichalel	and	P.P.	Sfikakis,	Circulating	levels	of	TNF-like	cytokine	1A	(TL1A)	and	its	decoy	receptor	3	(DcR3)	in	rheumatoid	arthritis,	Clin.
Immunol.	129,	2008,	249–255.
[6]	M.J.	Bull,	A.S.	Williams,	Z.	Mecklenburgh,	C.J.	Calder,	J.P.	Twohig,	C.	Elford,	B.A.J.	Evans,	T.F.	Rowley,	T.J.	Slebioda,	V.Y.	Taraban,	A.	Al-Shamkhani	and	E.C.Y.	Wang,	The	Death	Receptor	3-TNF-like	protein	1A	pathway	drives
adverse	bone	pathology	in	inflammatory	arthritis,	J.	Exp.	Med.	205,	2008,	2457–2464.
[7]	M.A.	Cassatella,	G.P.	da	Silva,	I.	Tinazzi,	F.	Facchetti,	P.	Scapini,	F.	Calzetti,	N.	Tamassia,	P.	Wei,	B.	Nardelli,	V.	Roschke,	A.	Vecchi,	A.	Mantovani,	L.M.	Bambara,	S.W.	Edwards	and	A.	Carletto,	Soluble	TNF-like	cytokine	(TL1A)
production	by	immune	complexes	stimulated	monocytes	in	rheumatoid	arthritis,	J.	Immunol.	178,	2007,	7325–7333.
[8]	K.	Osawa,	N.	Takami,	K.	Shiozawa,	A.	Hashiramoto	and	S.	Shiozawa,	Death	receptor	3	(DR3)	gene	duplication	in	a	chromosome	region	1p36.3:	gene	duplication	is	more	prevalent	in	rheumatoid	arthritis,	Genes	Immun.	5
2004,	439–443.
[9]	X.	Sun,	J.	Zhao,	R.	Liu,	R.	Jia,	L.	Sun,	X.	Li	and	Z.	Li,	Elevated	serum	and	synovial	fluid	TNF-like	ligand	1A	(TL1A)	is	associated	with	autoantibody	production	in	patients	with	rheumatoid	arthritis,	Scand.	J.	Rheumatol.
42,	2013,	97–101.
[10]	J.	Zhang,	X.	Wang,	H.	Fahmi,	S.	Wojcik,	J.	Fikes,	Y.	Yu,	J.	Wu,	H.	Luo,	J.	Zhang,	X.	Wang,	H.	Fahmi,	S.	Wojcik,	J.	Fikes,	Y.	Yu,	J.	Wu	and	H.	Luo,	Role	of	TL1A	in	the	pathogenesis	of	rheumatoid	arthritis,	J.	Immunol.	183,	2009,
5350–5357.
[11]	G.	Bamias,	C.	Martin,	M.	Marini,	S.	Hoang,	M.	Mishina,	W.G.	Ross,	M.A.	Sachedina,	C.M.	Friel,	J.	Mize,	S.J.	Bickston,	T.T.	Pizarro,	P.	Wei	and	F.	Cominelli,	Expression,	localization,	and	functional	activity	of	TL1A,	a	novel	Th1-
polarizing	cytokine	in	inflammatory	bowel	disease,	J.	Immunol.	171,	2003,	4868–4874.
[12]	G.	Bamias,	G.	Kaltsa,	S.I.	Siakavellas,	M.	Gizis,	G.	Margantinis,	E.	Zampeli,	I.	Vafiadis-Zoumboulis,	S.	Michopoulos,	G.L.	Daikos	and	S.D.	Ladas,	Differential	expression	of	the	TL1A/DcR3	system	of	TNF/TNFR-like	proteins	in
large	vs.	small	intestinal	Crohn’s	disease,	Dig.	Liver	Dis.	44,	2012,	30–36.
[13]	R.	Barrett,	X.	Zhang,	H.W.	Koon,	M.	Vu,	J.Y.	Chang,	N.	Yeager,	M.A.	Nguyen,	K.S.	Michelsen,	D.	Berel,	C.	Pothoulakis,	S.R.	Targan	and	D.Q.	Shih,	Constitutive	TL1A	expression	under	colitogenic	conditions	modulates	the
severity	and	location	of	gut	mucosal	inflammation	and	induces	fibrostenosis,	Am.	J.	Pathol.	180,	2012,	636–649.
[14]	S.	Jin,	J.	Chin,	S.	Seeber,	J.	Niewoehner,	B.	Weiser,	N.	Beaucamp,	J.	Woods,	C.	Murphy,	A.	Fanning,	F.	Shanahan,	K.	Nally,	R.	Kajekar,	A.	Salas,	N.	Planell,	J.	Lozano,	J.	Panes,	H.	Parmar,	J.	Demartino,	S.	Narula	and	D.A.	Thomas-
Karyat,	TL1A/TNFSF15	directly	induces	proinflammatory	cytokines,	including	TNFalpha,	from	CD3+CD161+	T	cells	to	exacerbate	gut	inflammation,	Mucosal	Immunol.	2012.
[15]	J.L.	Prehn,	S.	Mehdizadeh,	C.J.	Landers,	X.	Luo,	S.C.	Cha,	P.	Wei	and	S.R.	Targan,	Potential	role	for	TLlX	the	new	TNF-family	member	and	potent	costimulator	of	IFN-gamma,	in	mucosal	inflammation,	Clin.	Immunol.	112
2004,	66–77.
[16]	D.Q.	Shih,	L.Y.	Kwan,	V.	Chavez,	O.	Cohavy,	R.	Gonsky,	E.Y.	Chang,	C.	Chang,	C.O.	Elson,	S.R.	Targan,	D.Q.	Shih,	L.Y.	Kwan,	V.	Chavez,	O.	Cohavy,	R.	Gonsky,	E.Y.	Chang,	C.	Chang,	C.O.	Elson	and	S.R.	Targan,	Microbial
induction	of	inflammatory	bowel	disease	associated	gene	TL1A	(TNFSF15)	in	antigen	presenting	cells,	Eur.	J.	Immunol.	39,	2009,	3239–3250.
[17]	L.	Zheng,	X.	Zhang,	J.	Chen,	R.	Ichikawa,	K.	Wallace,	C.	Pothoulakis,	H.W.	Koon,	S.R.	Targan	and	D.Q.	Shih,	Sustained	TL1A	expression	on	both	lymphoid	and	myeloid	cells	leads	to	mild	spontaneous	intestinal
inflammation	and	fibrosis,	Eur.	J.	Microbiol.	Immunol.	(Bp)	3,	2013,	11–20.
[18]	G.	Bamias,	K.	Stamatelopoulos,	E.	Zampeli,	A.	Protogerou,	F.	Sigala,	C.	Papamichael,	P.	Christopoulos,	G.D.	Kitas	and	P.P.	Sfikakis,	Circulating	levels	of	TNF-like	cytokine	1A	correlate	with	the	progression	of	atheromatous
lesions	in	patients	with	rheumatoid	arthritis,	Clin.	Immunol.	147,	2013,	144–150.
[19]	E.C.	Wang,	Z.	Newton,	O.A.	Hayward,	S.R.	Clark,	F.	Collins,	W.V.	Perks,	R.K.	Singh,	J.P.	Twohig	and	A.S.	Williams,	Regulation	of	early	cartilage	destruction	in	inflammatory	arthritis	by	death	receptor	3,	Arthritis	Rheumatol.
66,	2014,	2762–2772.
[20]	F.L.	Collins,	J.O.	Williams,	A.C.	Bloom,	R.K.	Singh,	L.	Jordan,	M.D.	Stone,	L.R.	McCabe,	E.C.	Wang	and	A.S.	Williams,	CCL3	and	MMP-9	are	induced	by	TL1A	during	death	receptor	3	(TNFRSF25)-dependent	osteoclast
function	and	systemic	bone	loss,	Bone	97,	2017,	94–104.
[21]	F.L.	Collins,	J.O.	Williams,	A.C.	Bloom,	M.D.	Stone,	E.	Choy,	E.C.	Wang	and	A.S.	Williams,	Death	receptor	3	(TNFRSF25)	increases	mineral	apposition	by	osteoblasts	and	region	specific	new	bone	formation	in	the	axial
skeleton	of	male	DBA/1	mice,	J.	Immunol.	Res.	2015,	2015,	901679.
[22]	E.	Zinovieva,	C.	Bourgain,	A.	Kadi,	F.	Letourneur,	B.	Izac,	R.	Said-Nahal,	N.	Lebrun,	N.	Cagnard,	A.	Vigier,	S.	Jacques,	C.	Miceli-Richard,	H.J.	Garchon,	S.	Heath,	C.	Charon,	D.	Bacq,	A.	Boland,	D.	Zelenika,	G.	Chiocchia	and	M.
Breban,	Comprehensive	linkage	and	association	analyses	identify	haplotype,	near	to	the	TNFSF15	gene,	significantly	associated	with	spondyloarthritis,	PLoS	Genet.	5,	2009,	e1000528.
[23]	M.	Zucchelli,	M.	Camilleri,	A.N.	Andreasson,	F.	Bresso,	A.	Dlugosz,	J.	Halfvarson,	L.	Torkvist,	P.T.	Schmidt,	P.	Karling,	B.	Ohlsson,	R.H.	Duerr,	M.	Simren,	G.	Lindberg,	L.	Agreus,	P.	Carlson,	A.R.	Zinsmeister	and	M.	D'Amato,
Association	of	TNFSF15	polymorphism	with	irritable	bowel	syndrome,	Gut	60,	2011,	1671–1677.
[24]	K.	Yamazaki,	D.	McGovern,	J.	Ragoussis,	M.	Paolucci,	H.	Butler,	D.	Jewell,	L.	Cardon,	M.	Takazoe,	T.	Tanaka,	T.	Ichimori,	S.	Saito,	A.	Sekine,	A.	Iida,	A.	Takahashi,	T.	Tsunoda,	M.	Lathrop	and	Y.	Nakamura,	Single	nucleotide
polymorphisms	in	TNFSF15	confer	susceptibility	to	Crohn's	disease,	Hum.	Mol.	Genet.	14,	2005,	3499–3506.
[25]	K.S.	Michelsen,	L.S.	Thomas,	K.D.	Taylor,	Q.T.	Yu,	L.	Mei,	C.J.	Landers,	C.	Derkowski,	D.P.	McGovern,	J.I.	Rotter,	S.R.	Targan,	K.S.	Michelsen,	L.S.	Thomas,	K.D.	Taylor,	Q.T.	Yu,	L.	Mei,	C.J.	Landers,	C.	Derkowski,	D.P.B.	McGovern,
J.I.	Rotter	and	S.R.	Targan,	IBD-associated	TL1A	gene	(TNFSF15)	haplotypes	determine	increased	expression	of	TL1A	protein,	PLoS	One	4,	2009,	e4719.
[26]	D.Q.	Shih,	R.	Barrett,	X.	Zhang,	N.	Yeager,	H.W.	Koon,	P.	Phaosawasdi,	Y.	Song,	B.	Ko,	M.H.	Wong,	K.S.	Michelsen,	G.	Martins,	C.	Pothoulakis	and	S.R.	Targan,	Constitutive	TL1A	(TNFSF15)	expression	on	lymphoid	or	myeloid
cells	leads	to	mild	intestinal	inflammation	and	fibrosis,	PLoS	One	6,	2011,	e16090.
[27]	F.	Meylan,	Y.J.	Song,	I.	Fuss,	S.	Villarreal,	E.	Kahle,	I.J.	Malm,	K.	Acharya,	H.L.	Ramos,	L.	Lo,	M.M.	Mentink-Kane,	T.A.	Wynn,	T.S.	Migone,	W.	Strober	and	R.M.	Siegel,	The	TNF-family	cytokine	TL1A	drives	IL-13-dependent
small	intestinal	inflammation,	Mucosal	Immunol.	4,	2011,	172–185.
[28]	V.Y.	Taraban,	T.J.	Slebioda,	J.E.	Willoughby,	S.L.	Buchan,	S.	James,	B.	Sheth,	N.R.	Smyth,	G.J.	Thomas,	E.C.	Wang	and	A.	Al-Shamkhani,	Sustained	TL1A	expression	modulates	effector	and	regulatory	T-cell	responses	and
drives	intestinal	goblet	cell	hyperplasia,	Mucosal	Immunol.	4,	2011,	186–196.
[29]	F.	Meylan,	T.S.	Davidson,	E.	Kahle,	M.	Kinder,	K.	Acharya,	D.	Jankovic,	V.	Bundoc,	M.	Hodges,	E.M.	Shevach,	A.	Keane-Myers,	E.C.Y.	Wang	and	R.M.	Siegel,	The	TNF-family	receptor	DR3	is	essential	for	diverse	T	cell-
mediated	inflammatory	diseases,	Immunity	29,	2008,	79–89.
[30]	A.C.	Richard,	C.	Tan,	E.T.	Hawley,	J.	Gomez-Rodriguez,	R.	Goswami,	X.P.	Yang,	A.C.	Cruz,	P.	Penumetcha,	E.T.	Hayes,	M.	Pelletier,	O.	Gabay,	M.	Walsh,	J.R.	Ferdinand,	A.	Keane-Myers,	Y.	Choi,	J.J.	O'Shea,	A.	Al-Shamkhani,	M.H.
Kaplan,	I.	Gery,	R.M.	Siegel	and	F.	Meylan,	The	TNF-family	ligand	TL1A	and	its	receptor	DR3	promote	T	cell-mediated	allergic	immunopathology	by	enhancing	differentiation	and	pathogenicity	of	IL-9-producing	T
cells,	J.	Immunol.	194,	2015,	3567–3582.
[31]	E.M.	Hessel,	A.J.M.	Van	Oosterhout,	C.L.	Hofstra,	J.J.	De	Bie,	J.	Garssen,	H.	Van	Loveren,	A.K.C.P.	Verheyen,	H.F.J.	Savelkoul	and	F.P.	Nijkamp,	Bronchoconstriction	and	airway	hyperresponsiveness	after	ovalbumin	inhalation
in	sensitized	mice,	Eur.	J.	Pharmacol.	293,	1995,	401–412.
[32]	A.B.	Kay,	Pathology	of	mild,	severe,	and	fatal	asthma,	Am.	J.	Respir.	Crit.	Care	Med.	154,	1996,	S66–S69.
[33]	E.C.Y.	Wang,	A.	Thern,	A.	Denzel,	J.	Kitson,	S.N.	Farrow	and	M.J.	Owen,	DR3	regulates	negative	selection	during	thymocyte	development,	Mol.	Cell.	Biol.	21,	2001,	3451–3461.
[34]	S.	Fernandez-Rodriguez,	W.R.	Ford,	K.J.	Broadley	and	E.J.	Kidd,	Establishing	the	phenotype	in	novel	acute	and	chronic	murine	models	of	allergic	asthma,	Int.	Immunopharmacol.	8,	2008,	756–763.
[35]	T.	Ashcroft,	J.M.	Simpson	and	V.	Timbrell,	Simple	method	of	estimating	severity	of	pulmonary	fibrosis	on	a	numerical	scale,	J.	Clin.	Pathol.	41,	1988,	467–470.
[36]	L.	Fang,	B.	Adkins,	V.	Deyev	and	E.R.	Podack,	Essential	role	of	TNF	receptor	superfamily	25	(TNFRSF25)	in	the	development	of	allergic	lung	inflammation,	J.	Exp.	Med.	205,	2008,	1037–1048.
[37]	W.V.	Perks,	R.K.	Singh,	G.W.	Jones,	J.P.	Twohig,	A.S.	Williams,	I.R.	Humphreys,	P.R.	Taylor,	S.A.	Jones	and	E.C.	Wang,	Death	receptor	3	promotes	chemokine-directed	leukocyte	recruitment	in	acute	resolving	inflammation
and	is	essential	for	pathological	development	of	mesothelial	fibrosis	in	chronic	disease,	Am.	J.	Pathol.	186,	2016,	2813–2823.
[38]	G.	Bamias,	K.	Evangelou,	T.	Vergou,	K.	Tsimaratou,	G.	Kaltsa,	C.	Antoniou,	A.	Kotsinas,	S.	Kim,	V.	Gorgoulis,	A.J.	Stratigos	and	P.P.	Sfikakis,	Upregulation	and	nuclear	localization	of	TNF-like	cytokine	1A	(TL1A)	and	its
receptors	DR3	and	DcR3	in	psoriatic	skin	lesions,	Exp.	Dermatol.	20,	2011,	725–731.
[39]	R.S.	Al-Lamki,	J.	Wang,	S.	Thiru,	N.R.	Pritchard,	J.A.	Bradley,	J.S.	Pober	and	J.R.	Bradley,	Expression	of	silencer	of	death	domains	and	death-receptor-3	in	normal	human	kidney	and	in	rejecting	renal	transplants,	Am.	J.
Pathol.	163,	2003,	401–411.
[40]	M.	Facco,	A.	Cabrelle,	F.	Calabrese,	A.	Teramo,	F.	Cinetto,	S.	Carraro,	V.	Martini,	F.	Calzetti,	N.	Tamassia,	M.A.	Cassatella,	G.	Semenzato	and	C.	Agostini,	TL1A/DR3	axis	involvement	in	the	inflammatory	cytokine	network
during	pulmonary	sarcoidosis,	Clin.	Mol.	Allergy	13,	2015,	16.
[41]	R.K.	Kumar	and	P.S.	Foster,	Modeling	allergic	asthma	in	mice,	Am.	J.	Respir.	Cell	Mol.	Biol.	27,	2002,	267–272.
[42]	L.	Swedin,	R.	Ellis,	C.	Kemi,	A.	Ryrfeldt,	M.	Inman,	S.E.	Dahlen	and	M.	Adner,	Comparison	of	aerosol	and	intranasal	challenge	in	a	mouse	model	of	allergic	airway	inflammation	and	hyperresponsiveness,	Int.	Arch.
Allergy	Immunol.	153,	2010,	249–258.
[43]	K.E.	Driscoll,	D.L.	Costa,	G.	Hatch,	R.	Henderson,	G.	Oberdorster,	H.	Salem	and	R.B.	Schlesinger,	Intratracheal	instillation	as	an	exposure	technique	for	the	evaluation	of	respiratory	tract	toxicity:	uses	and	limitations,
Toxicol.	Sci.	55,	2000,	24–35.
[44]	E.R.	Jarman	and	J.R.	Lamb,	Chronic	models	of	airway	inflammation,	mucus	hypersecretion	and	remodelling,	Drug	Discov.	Today	2,	2005,	119–126.
[45]	M.	Wills-Karp,	Immunologic	basis	of	antigen-induced	airway	hyperresponsiveness,	Annu.	Rev.	Immunol.	17,	1999,	255–281.
[46]	K.	Sakai,	A.	Yokoyama,	N.	Kohno,	H.	Hamada	and	K.	Hiwada,	Prolonged	antigen	exposure	ameliorates	airway	inflammation	but	not	remodeling	in	a	mouse	model	of	bronchial	asthma,	Int.	Arch.	Allergy	Immunol.	126,
2001,	126–134.
[47]	C.	Koerner-Rettberg,	S.	Doths,	A.	Stroet	and	J.	Schwarze,	Reduced	lung	function	in	a	chronic	asthma	model	is	associated	with	prolonged	inflammation,	but	independent	of	peribronchial	fibrosis,	PLoS	One	3,	2008,
e1575.
[48]	F.K.	Swirski,	D.	Sajic,	C.S.	Robbins,	B.U.	Gajewska,	M.	Jordana	and	M.R.	Stampfli,	Chronic	exposure	to	innocuous	antigen	in	sensitized	mice	leads	to	suppressed	airway	eosinophilia	that	is	reversed	by	granulocyte
macrophage	colony-stimulating	factor,	J.	Immunol.	169,	2002,	3499–3506.
[49]	N.R.	Locke,	S.G.	Royce,	J.S.	Wainewright,	C.S.	Samuel	and	M.L.	Tang,	Comparison	of	Airway	Remodeling	in	Acute,	Subacute,	and	Chronic	Models	of	Allergic	Airways	Disease,	Am.	J.	Respir.	Cell	Mol.	Biol.	36,	2007,
625–632.
[50]	D.G.	Rudmann,	M.W.	Moore,	J.S.	Tepper,	M.C.	Aldrich,	J.W.	Pfeiffer,	H.	Hogenesch	and	D.B.	Tumas,	Modulation	of	allergic	inflammation	in	mice	deficient	in	TNF	receptors,	Am.	J.	Physiol.	Lung	Cell.	Mol.	Physiol.	279,	2000,
L1047–L1057.
[51]	T.H.	Schreiber,	D.	Wolf,	M.S.	Tsai,	J.	Chirinos,	V.V.	Deyev,	L.	Gonzalez,	T.R.	Malek,	R.B.	Levy	and	E.R.	Podack,	Therapeutic	Treg	expansion	in	mice	by	TNFRSF25	prevents	allergic	lung	inflammation,	J.	Clin.	Invest.	120,
2010,	3629–3640.
[52]	S.Q.	Khan,	M.S.	Tsai,	T.H.	Schreiber,	D.	Wolf,	V.V.	Deyev	and	E.R.	Podack,	Cloning,	expression,	and	functional	characterization	of	TL1A-Ig,	J.	Immunol.	190,	2013,	1540–1550.
[53]	T.	Tschernig	and	R.	Pabst,	What	is	the	clinical	relevance	of	different	lung	compartments?,	BMC	Pulm.	Med.	2009,	39.
[54]	S.	Laberge,	S.	El	Bassam.
[55]	H.	Kitamura,	S.	Cambier,	S.	Somanath,	T.	Barker,	S.	Minagawa,	J.	Markovics,	A.	Goodsell,	J.	Publicover,	L.	Reichardt,	D.	Jablons,	P.	Wolters,	A.	Hill,	J.D.	Marks,	J.	Lou,	J.F.	Pittet,	J.	Gauldie,	J.L.	Baron	and	S.L.	Nishimura,	Mouse
and	human	lung	fibroblasts	regulate	dendritic	cell	trafficking,	airway	inflammation,	and	fibrosis	through	integrin	alphavbeta8-mediated	activation	of	TGF-beta,	J.	Clin.	Invest.	121,	2011,	2863–2875.
[56]	C.L.	Ordonez,	R.	Khashayar,	H.H.	Wong,	R.	Ferrando,	R.	Wu,	D.M.	Hyde,	J.A.	Hotchkiss,	Y.	Zhang,	A.	Novikov,	G.	Dolganov	and	J.V.	Fahy,	Mild	and	moderate	asthma	is	associated	with	airway	goblet	cell	hyperplasia	and
abnormalities	in	mucin	gene	expression,	Am.	J.	Respir.	Crit.	Care	Med.	163,	2001,	517–523.
[57]	J.	von	Moltke,	M.	Ji,	H.E.	Liang	and	R.M.	Locksley,	Tuft-cell-derived	IL-25	regulates	an	intestinal	ILC2-epithelial	response	circuit,	Nature	529,	2016,	221–225.
[58]	D.Q.	Shih,	L.	Zheng,	X.	Zhang,	H.	Zhang,	Y.	Kanazawa,	R.	Ichikawa,	K.L.	Wallace,	J.	Chen,	C.	Pothoulakis,	H.W.	Koon	and	S.R.	Targan,	Inhibition	of	a	novel	fibrogenic	factor	Tl1a	reverses	established	colonic	fibrosis,	Mucosal
Immunol.	7,	2014,	1492–1503.
[59]	C.G.	Lee,	R.J.	Homer,	Z.	Zhu,	S.	Lanone,	X.	Wang,	V.	Koteliansky,	J.M.	Shipley,	P.	Gotwals,	P.	Noble,	Q.	Chen,	R.M.	Senior	and	J.A.	Elias,	Interleukin-13	induces	tissue	fibrosis	by	selectively	stimulating	and	activating
transforming	growth	factor	beta(1),	J.	Exp.	Med.	194,	2001,	809–821.
[60]	T.A.	Doherty,	P.	Soroosh,	N.	Khorram,	S.	Fukuyama,	P.	Rosenthal,	J.Y.	Cho,	P.S.	Norris,	H.	Choi,	S.	Scheu,	K.	Pfeffer,	B.L.	Zuraw,	C.F.	Ware,	D.H.	Broide	and	M.	Croft,	The	tumor	necrosis	factor	family	member	LIGHT	is	a
target	for	asthmatic	airway	remodeling,	Nat.	Med.	17,	2011,	596–603.
[61]	Y.S.	Cho,	B.	Kwon,	T.H.	Lee,	T.B.	Kim,	K.A.	Moon,	S.	La,	J.	Lee,	S.D.	Lee,	Y.M.	Oh	and	H.B.	Moon,	4-1	BB	stimulation	inhibits	allergen-specific	immunoglobulin	E	production	and	airway	hyper-reactivity	but	partially
suppresses	bronchial	eosinophilic	inflammation	in	a	mouse	asthma	model,	Clin.	Exp.	Allergy	36,	2006,	377–385.
Queries	and	Answers
Query:	Your	article	is	registered	as	a	regular	item	and	is	being	processed	for	inclusion	in	a	regular	issue	of	the	journal.	If	this	is	NOT	correct	and	your	article	belongs	to	a	Special	Issue/Collection	please
contact	d.krishnan@elsevier.com	immediately	prior	to	returning	your	corrections.
Answer:	this	is	correct
Query:	The	author	names	have	been	tagged	as	given	names	and	surnames	(surnames	are	highlighted	in	teal	color).	Please	confirm	if	they	have	been	identified	correctly.
Answer:	yes
Query:	Please	provide	affiliations	for	all	the	authors.
Answer:	Singh,	perks,	twohig,	williams,	taylor,	wang:	*Division	of	Infection	&	Immunity,	School	of	Medicine,	Cardiff	University,	Heath	Park,	Cardiff	CF14	4XN,	UK	.	Kidd,	Broadley:	School	of	Pharmacy
and	Pharmaceutical	Sciences,	Cardiff	University,	Cardiff	CF10	3NB,	UK	.	Farrow:	CRT	discoveries	laboratories,	Babraham	Research	Campus,	Cambridge	CB22	3AT,	UK
Query:	Please	provide	complete	details	for	Ref.	[54].
Answer:	S.	Laberge,	S.	El	Bassam,	Cytokines,	structual	cells	of	the	lung	and	airway	inflammation,	Paediatric	Respiratory	Reviews.	5,	2004,	S41-45.
Highlights
• DR3	has	distinctive	roles	in	acute	and	chronic	stages	of	allergic	lung	inflammation.
• In	acute	lung	inflammation,	DR3ko	mice	are	protected	from	lung	cell	infiltration.
• In	chronic	lung	disease,	DR3	is	essential	for	goblet	cell	hyperplasia.
• Conclude	that	DR3	may	be	required	for	the	development	of	lung	pathology.
